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GLUT2-mediated uptake provides a low-affinity, high-
capacity route for glucose to enter proximal tubule cells
during hyperglycemia and might therefore initiate the
changes in cellular carbohydrate metabolism that have been
linked to diabetic nephropathy. It is noteworthy that the
Fanconi–Bickel syndrome, which is associated with glycogen
accumulation in proximal tubule cells and a diabetic-like
nephropathy, has been linked to mutations of the GLUT2
gene.4 The emerging importance of GLUT2 in proximal
tubule physiology suggests that expression of the transporter
should be a major focus when considering the implications of
chronic hyperglycemia for tubular damage.
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To the Editor: We agree with Dr Debnam that high glucose
condition has a variety of effects on glucose transporters
[Naþ /glucose cotransporters (SGLTs) and facilitated diffu-
sion glucose transporters (GLUTs)].1 However, some studies
have yielded conflicting results on the effects of diabetes
conditions on SGLT-mediated glucose transport. Studies have
reported both increased2 and decreased3 glucose transport
mediated by SGLT in diabetes. In our previous studies, when
primary proximal tubule cells (PTCs) were cultured in high
glucose, the SGLTs were inhibited through reactive oxygen
species, Ca2þ /PKC, cPLA2/AA, as well as NF-kB pathways.
4
Primary cultured PTCs are a convenient means to evaluate
the activity of glucose transporters because the kidney cell
lines may have been changed and reduced activities of the
transporter or enzyme after few passages. Instead of the
serum-supplemented media (cause of fibroblast overgrowth),
hormonally defined and serum-free conditions, supple-
mented with insulin, transferrin, and hydrocortisone, could
maintain primary cultured PTCs to have a polarized
morphology and distinctive proximal tubule functions.
Therefore, PTCs in hormonally defined, serum-free culture
conditions would be a powerful tool for studying the
alteration of glucose cotransporters activity.5 In our opinion,
the discrepancies among results may be due to the difference
of experimental model (in vivo vs in vitro), species (rat vs
rabbit), cell culture condition (serum-supplemented media vs
hormonally defined and serum-free media), and/or cell
specificity (primary cultured cells vs cell lines). Therefore,
our studies suggest that high glucose-mediated abnormal
glucose handling in the proximal tubule may play an
important part in the development of diabetic nephropathy,
although renal PTCs do not seem to be primary targets for
diabetic injury.
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To the Editor: In a recent publication, Chung et al.1 showed
the images of bilateral adrenal nodular lesions as bilateral
aldosterone producing adenomas. Although the surgical
resection of the both lesions corrected the clinical symptoms
of primary aldosteronism, we think that the only one lesion
might have been an aldosterone producing adenoma.
Because the radiolabeled cholesterol analogs concentrate
in steroid hormone-synthesizing tissues, the scintigraphy
with them is used for determining the site of excess hormone
secretion.2 However, it is reported that the uptake primarily
depends on the adenoma volume,3 and that the diagnostic
accuracy of the scintigraphy for aldosterone producing
ademonas, which are generally small, is not high even after
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dexamethasone suppression.4 Therefore, although Chung
et al. used the dexamethasone-suppression adrenocortical
scintigraphy to show the functional activity of the lesions, the
diagnosis based only on the scintigraphy could lead to
misdiagnosis.5
The CT image Chung et al. presented showed different
contrast enhancement effect in the adrenal lesions, which
indicates that the lesions would have different nature.
Considering that the existence of adrenal nodular lesions in
the patients with hypertension is reported to be not rare,6,7 it
is possible that the only one lesion had aldosterone hyper-
secretion. Because the small size and the NP-59 accumulation
in the case presented by Chung et al. indicate the benign
nature of the lesions,6–8 the resection of the only one lesion
with aldosterone hypersecretion might have been sufficient.
Adrenal vein sampling is now considered to be the most
reliable diagnostic test to detect the site of aldosterone
hypersecretion.9,10 Therefore, we would like to recommend
adrenal vein sampling in the cases under the suspicion of
primary aldosteronism, such as the case presented by Chung
et al. The lesions should better be resected after the
confirmation of their functional activity.
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We certainly appreciated the comments by Dr Tanemoto
et al.1 regarding our report of Diagnosis of bilateral
aldosterone-producing adenomas.2
The preoperative diagnosis of bilateral aldosterone-
producing adenomas remains elusive and can only be
definitely made postoperatively by pathological existence
of typical adenomas in the excised specimen, and strong
expression of the aldosterone synthase by real-time PCR of
the excised tumor.3
Although computed tomography (CT) scanning might
not reliably discriminate bilateral adrenal hyperplasia
(BAH) from aldosterone-producing adenoma (APA),4 pre-
vious reports showed that the finding of a single-focal
macroadenoma on CT scan had a high positive predictive
value when the tumor size was 41.0 cm;5,6 and it will be
more diagnostic of APA when combined with a positive
NP-59 adrenocortical scintigraphy as a valid evaluation tool
for primary aldosteronism.7 Even adrenal vein sampling
(AVS), the gold standard of differential diagnosis of the
subtypes of primary aldosteronism, has its limitation
because of bilateral functional adenomas that may be
present at the same time or metachronously. In our institute,
there were four cases of simultaneous bilateral aldosterone-
producing adenomas among 164 APA patients surgically
treated and which were pathologically documented as APAs.
These four bilateral aldosterone-producing adenoma
patients presented with evidence of bilateral localized up-
takes of NP-59 at dexamethasone-suppressed adrenocortical
scintigraphy, with CT scan demonstrating tumors larger
than 1.0 cm in diameter (1.2–2.0 cm, mean 1.5 cm) and
negative postural test before operation. There were another
three cases of metachronous bilateral aldosterone-producing
adenomas, with the second contralateral tumor clinically
detectable 18–48 months after the first adrenalectomy.8
For this specific patient presented in our report, we also
performed real-time PCR of the aldosterone synthase.2 The
mRNA level of aldosterone synthase (CYP11B2) were
corrected with the mRNA level of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), and were quantified using real-
time PCR as previously reported,3 and it is expressed as
2DDCT, where DDCT¼ (DCT CYP11B2DCT GAPDH). The
mRNA level of the bilateral tumorous portions and the
nontumorous portions were DDCT, 2.73±0.13 versus 12.47±
0.68 in this patient, indicating much higher mRNA activity in
bilateral tumors, and proved that they both are functional
APAs. And a radiologist was asked to review the CT scans
of that patient again which revealed that his bilateral tumors
were larger than 1.0 cm, and both were enhanced with
contrast medium.
In conclusion, we believed that it is reasonable to
perform bilateral subtotal adrenalectomies in treating
bilateral APAs, which present with aldosterone–renin ratio
4100 ng per 100 ml per ng ml1 h1, plasma aldosterone
420 ng per 100 ml, and bilateral macronodular tumors
(41.0 cm) and positive uptake in the adrenal scan.
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